ERIK PAGE AND ASSOCIATES, INC.

Medtech

A device that monitors and controls circadian light stimulus (CS) in nursing home environments to optimize lighting for Alzheimer's disease patients

Grants
$1.9M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Device to measure circadian-effective light in Alzheimer's disease environments$225,000
Federal grantDepartment of Health and Human Services · Phase II · Device to control circadian-effective light in Alzheimer's disease environments$1,240,470
Federal grantDepartment of Health and Human Services · Phase II · Device to control circadian-effective light in Alzheimer's disease environments$432,887
Federal grantDepartment of Health and Human Services · Phase II · Device to control circadian-effective light in Alzheimer's disease environments$10,487
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
732NEUROTARGETING SYSTEMS——
733Global Innovative Platforms Inc.—$470K
734SENSVITA INC.——
735ERIK PAGE AND ASSOCIATES, INC.——
736COOLTECH LLC—$1.1M
737MICROMED CARDIOVASCULAR INC—$11M
738ALEO BME INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.